OCRA has awarded 450+ grants and invested $140 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
OCRA has awarded 450+ grants and invested $140 million in ovarian cancer and related gynecologic cancer research initiatives, becoming the largest global charity devoted to ovarian and related gynecologic cancer research in the world.
Our commitment to cutting-edge research has resulted in scientific breakthroughs that are igniting hope worldwide and galvanizing top researchers as never before.
OCRA is proud to support groundbreaking ovarian cancer and related gynecologic cancer research. With an annual grantmaking budget of over $7 million, we fund scientists at all stages of their careers. OCRA-funded scientists are working in areas ranging from AI and basic science to clinical and translational research. They are also exploring disease at the cellular and molecular level.
Ovarian Cancer Research Alliance is proud to present the 16th Biennial Ovarian Cancer Research Symposium. The event will take place in Philadelphia on October 16-18, 2026.
Our researchers come from across the country and around the globe. While their areas of research may differ, they are united in their passion to find a cure and their desire to collaborate and innovate to improve the lives of patients.
OCRA’s new research partnership, The Edmée Firth Fund for Research in Ovarian Cancer (EFFROC), is funding research to develop clinical testing methods and education to increase physicians’ awareness of the disease and the importance of early detection. It is also funding research into ways to reduce the toxicity and side effects of second-line treatments and to improve targeted therapies.
Accelerating the Mission: OCRA President & CEO Audra Moran Named a Crain’ 2026 Notable Leader in Health Care Ovarian Cancer Research Alliance (OCRA) is proud to share that President and CEO Audra Moran has been named a Crain’s New York Business 2026 Notable Leader in Health Care—an annual recognition honoring executives whose leadership, innovation, and … Continued
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
Get email updates about research news, action alerts, and ways to join the fight.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
